Which is better IL-17 or IL-23 inhibitors?

IL-17 inhibitors work faster, while IL-23 inhibitors provide longer-lasting disease control. The best choice depends on the patient's condition and treatment goals.

Do IL-23 inhibitors reduce inflammation more effectively?

IL-23 inhibitors act upstream in the inflammatory pathway, which may provide broader and more sustained suppression of inflammation.

Do these biologics reduce cardiovascular risk?

Yes. Both IL-17 and IL-23 inhibitors are associated with reduced cardiovascular risk by lowering systemic inflammation in psoriasis patients.

IL‑17 vs IL‑23 Biologics in Psoriasis: What’s the Difference?

Understanding the Differences Between IL-17 and IL-23 Biologics in Psoriasis

What is the difference between IL‑17 and IL‑23 biologics?

IL‑17 biologics act downstream to block inflammatory signals that directly cause psoriasis plaques, producing rapid skin clearance. IL‑23 biologics act upstream, preventing the activation of the inflammatory cascade, leading to longer-lasting control and potentially broader systemic benefits.

Clinical infographic comparing IL‑17 and IL‑23 biologic pathways in psoriasis inflammation, showing dendritic cell activation, T‑cell differentiation, cytokine release, and skin inflammation outcomes

This side‑by‑side infographic illustrates how IL‑17 drives direct inflammation through keratinocyte activation and neutrophil recruitment, while IL‑23 acts upstream, regulating Th17 and Th22 cells to sustain chronic psoriasis inflammation.

Modern psoriasis treatment has shifted toward targeted biologic therapies, particularly those blocking the IL‑23 / IL‑17 inflammatory axis, which plays a central role in disease progression. [1](https://link.springer.com/content/pdf/10.1007/s13555-021-00483-2.pdf)

Understanding the IL‑23 / IL‑17 Pathway

Psoriasis develops when immune signals trigger excessive skin cell growth. The IL‑23/IL‑17 pathway drives this process:

IL‑23: activates immune cells (Th17 cells)
IL‑17: directly stimulates skin inflammation and plaque formation

IL‑23 essentially turns on the inflammatory cascade, while IL‑17 executes the inflammatory response at the skin level. [2](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2821%2900184-7/fulltext)

Key Differences: IL‑17 vs IL‑23 Biologics

Feature	IL‑17 Inhibitors	IL‑23 Inhibitors
Target	Downstream cytokine (IL‑17)	Upstream regulator (IL‑23)
Speed of effect	Rapid onset of action	Slower but sustained response
Skin clearance	Very high, fast improvement	High and durable clearance
Long-term control	Effective, but may vary	Strong long-term persistence
Best for	Rapid symptom relief, psoriatic arthritis	Long-term disease control, metabolic risk

Clinical Advantages of IL‑17 Inhibitors

Fastest onset of action among biologics [3](https://thedermdigest.com/il-17-vs-il-23-the-latest-comparison/)
Strong effectiveness in psoriatic arthritis and joint disease [3](https://thedermdigest.com/il-17-vs-il-23-the-latest-comparison/)
High rates of rapid skin clearance

These features make IL‑17 inhibitors ideal when quick symptom improvement is needed.

Clinical Advantages of IL‑23 Inhibitors

Long-lasting disease control
Upstream targeting may reduce inflammatory signaling more broadly
Strong treatment persistence over time

IL‑23 inhibitors may provide more durable remission and systemic inflammation control.

Cardiovascular and Mortality Considerations

Both IL‑17 and IL‑23 inhibitors are associated with reduced cardiovascular risk compared to untreated psoriasis. [4](https://www.dermatologytimes.com/view/il-23-and-il-17-inhibitors-reduce-cardiovascular-outcomes-in-statin-treated-psoriasis-patients)

IL‑23 inhibitors may show stronger reductions in cardiovascular events in some studies [4](https://www.dermatologytimes.com/view/il-23-and-il-17-inhibitors-reduce-cardiovascular-outcomes-in-statin-treated-psoriasis-patients)
Both classes lower systemic inflammation linked to heart disease
Major cardiovascular event rates appear similar between groups in long-term comparisons [5](https://www.dermatologyadvisor.com/reports/safety-outcomes-vary-il-23-il-17-inhibitor-use-psoriasis/)

This supports the concept that targeting inflammation directly improves long-term health outcomes.

Safety Differences

IL‑23 inhibitors: lower infection risk in some analyses [5](https://www.dermatologyadvisor.com/reports/safety-outcomes-vary-il-23-il-17-inhibitor-use-psoriasis/)
IL‑17 inhibitors: reliable safety profile with strong clinical data
Each class has different risk considerations based on patient history

Safety profiles are broadly favorable, but therapy should always be individualized.

Which Is Better?

It depends on the patient.

Choose IL‑17 inhibitors for rapid clearance and joint involvement
Choose IL‑23 inhibitors for sustained remission and metabolic risk concerns

Both classes are highly effective and superior to older systemic therapies in many cases. [6](https://www.emjreviews.com/allergy-immunology/article/il-17-and-23-inhibitors-for-the-treatment-of-psoriasis/)

How to Choose a Biologic for Psoriasis

Choosing between IL‑17 and IL‑23 biologics depends on your clinical needs, goals, and risk profile.

Quick answer: IL‑17 inhibitors are best for rapid symptom relief and joint involvement, while IL‑23 inhibitors are preferred for long-term disease control and sustained remission. The ideal choice depends on disease severity, comorbidities, and treatment goals.

Step-by-Step: Selecting the Right Biologic

Assess disease severity and urgency
Choose an IL‑17 inhibitor if rapid skin clearance is needed. These therapies act quickly on inflammation and often produce faster visible results.
Evaluate long-term disease control goals
IL‑23 inhibitors are better suited for patients seeking durable remission and fewer dosing intervals.
Consider psoriatic arthritis or joint symptoms
IL‑17 inhibitors are often preferred for patients with joint involvement due to strong effectiveness in psoriatic arthritis.
Review metabolic and cardiovascular risk
Both classes reduce systemic inflammation, but IL‑23 inhibitors may have advantages for long-term systemic control based on emerging data.
Account for patient-specific factors
Include:
- Previous biologic response
- Body weight and metabolic health
- Injection frequency preferences
- Comorbid conditions
Discuss risks and benefits with a clinician
A personalized approach ensures optimal outcomes and safety.

Biologic Selection at a Glance

Choose IL‑17 inhibitors if:
- Rapid symptom improvement is needed
- Psoriatic arthritis is present
- Fast skin clearance is a priority
Choose IL‑23 inhibitors if:
- Long-term disease control is the goal
- You want durable remission
- Fewer injections are preferred

Clinical Summary

The IL‑23 / IL‑17 pathway drives psoriasis inflammation
IL‑17 inhibitors act quickly on downstream inflammation
IL‑23 inhibitors provide more durable long-term control
Both reduce systemic inflammatory burden and cardiovascular risk
Treatment choice should be individualized

Clinical Evidence & References

This article reflects current scientific understanding of psoriasis and biologic therapies targeting the IL‑23 / IL‑17 pathway.

Review articles describing the IL‑23 / IL‑17 axis as a central driver of psoriasis inflammation and comorbid disease.
Clinical trials and meta‑analyses demonstrating high efficacy of IL‑17 and IL‑23 inhibitors in achieving skin clearance and reducing disease activity.
Observational and registry studies evaluating cardiovascular outcomes and systemic inflammation reduction with biologic therapy.
Dermatology guidelines and consensus statements supporting targeted biologics for moderate‑to‑severe psoriasis.

Clinical interpretation: Biologic therapy decisions should consider individual patient factors, including disease severity, metabolic risk, and comorbid conditions.